Genmab A (GMAB) Tax Provisions (2024 - 2026)

Genmab A (GMAB) has reported Tax Provisions for 3 consecutive years, with $8.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions rose 105.88% year-over-year to $8.0 million; the trailing twelve-month figure through Jun 2026 stood at $32.0 million (changed N/A YoY), and the FY2025 full-year result was $241.0 million, up 24.87% from the prior year.
• Tax Provisions advanced to $8.0 million in Q2 2026 per GMAB's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $161.0 million in Q2 2024 and bottomed at -$136.0 million in Q2 2025.
• Historically, Tax Provisions has averaged $8.0 million across 3 years, with a median of $3.5 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Tax Provisions slumped 184.47% in 2025, then surged 105.88% in 2026.
• Over 3 years, Tax Provisions stood at $161.0 million in 2024, then plunged by 184.47% to -$136.0 million in 2025, then soared by 105.88% to $8.0 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $8.0 million, -$1.0 million, and -$136.0 million for Q2 2026, Q1 2026, and Q2 2025 respectively.